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G. Fluge6, for the Scandinavian CF Study Consortium. 1Karolinska University
Hospital Huddinge, Stockholm, Sweden; 2Aarhus University Hospital, Aarhus,
Denmark; 3Ullevaal University Hospital, Oslo, Norway; 4Rigshospitalet,
Copenhagen, Denmark; 5Goteborg University Hospital, Gothenburg, Sweden;
6Haukeland University Hospital, Bergen, Norway
898 (430 F) Scandinavian CF patients took part in a comprehensive study of their
nutritional status, 7/8 CF centers participating. Median age was 18.3 (0.3−65.9) y.
As part of the study the pancreatic enzyme replacement therapy was investigated.
Results: 771 patients were pancreatic insufﬁcient. Enzyme preparations used: low
dose (5,500 lipase) 28%, medium dose (10,000 lipase) 51% and high dose (25,000
lipase) 17%. Use of high lipase preparations increased with age and differed
markedly between centres (from Copenhagen 0% to Oslo 48%). Units of lipase
differed between countries and between children and adults. Median units of
lipase/kg BW per principal meal for children (adults) were: Denmark 3077 (2069),
Norway 1389 (842), Sweden 1852 (912) (all p< 0.001 except adults in N and S).
Patients on proton pump blockers had a higher intake of units of lipase. Boys had
a higher lipase intake than girls, though not signiﬁcant (p = 0.12). There was no
correlation between units of lipase/kg BW per principal meal and frequency of
DIOS. Preliminary data show reported amount lipase intake to be higher than that
registered in the 7-day precoded dietary food record.
Conclusions: Danish CF patients had a higher intake of lipase than CF patients in
Norway and Sweden but used no high lipase preparations. A subgroup of patients
having a large intake of lipase needs to be investigated further.
Supported by: Swedish Heart Lung Foundation, Stiftelsen Frimurare-Barnhuset i
Stockholm, Norwegian CF Association, Swedish CF Association and an unrestricted
grant by Solvay Pharma (Denmark, Sweden and Norway).
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Introduction: Patients with Cystic Fibrosis (CF) may develop single or sometimes
recurrent bouts of acute pancreatitis and this complication has been mostly reported
in adolescents or adults with a pancreatic sufﬁcient (PS) phenotype. In addition
patients with idiopathic chronic pancreatitis are often found to carry mild CFTR
mutations.
Goal: To describe the features of a group of CF patients who had pancreatitis and
to investigate its prevalence and possible risk-factors.
Patients and Methods: The clinical records of patients with CF under care in
5 CF Units who had a diagnosis of pancreatitis were reviewed and clinical and
genetic details are presented.
Results: Fifteen out of 485 (3.1%) patients had pancreatitis, 66.7% males, average
age 15.04 years. In 3 (20%) pancreatitis preceded the diagnosis of CF. Eight (53.3%)
had a single episode, 4 (26.7%) had 2 and 3 (20%) had multiple bouts.
Clinical features: Nutrition (Weight >P10 80%, Heigth >P10 73.3%), No &
Mild lung disease 73.3%, Pancreatic insufﬁciency (PI) 53.3%, Nasal polyps &
Sinusitis 46.6%, Liver disease 33.3%, Hypochloremic alcalosis 33.3%, Meconium
ileus/DIOS 20%, Glucose intolerance 13.3%
Genotype: F508del/F508del 3 (All PI), F508del/− 5 (2 PI), F508del/R347H 1 (PS),
F508del/G85E 1 (PI), F508del/3272−26A>G 1 (PS), F508del/R334W 1 (PS),
L206W/S549R 1 (PS), G542X/2789+5G>A 1 (PI), R347P/− 1 (PI).
Conclusions: The prevalence of pancreatitis in this study was 3.1% and over half
of the patients had pancretic insufﬁciency underlying that this complication in not
restricted to patients carrying mild mutations.
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Introduction: Cystic Fibrosis (CF) is the commonest genetically inherited disease.
Abnormal bile composition causes biliary stasis leading to CF liver disease (CFLD)
& portal hypertension. Increased longevity means CFLD is now associated with with
signiﬁcant morbidity. Many patients present with established CFLD, when potential
therapies eg ursodeoxycholic acid (UDCA) are ineffective. Current diagnostic tests
(clinical examination, LFTs) are insufﬁcient for early detection of CFLD. Detailed
US scanning may be more sensitive in early detection & prospective evaluation of
CFLD.
Aims: To describe the use of a new ultrasound (US) scoring system-the Stewart
Ultrasound Score (SUSS), in CF children with & without clinical/biochemical
evidence of liver disease.
Methods: Annual review (prospective & retrospective) of 241 CF children over
2 years: 66 CFnoLD patients (4m-16 yrs) & 175 CFLD (3m – 17 yrs).CFnoLD
= normal LFTs/clinical examination. Data analysed: abdominal US, LFTs, lung
function, height/weight & clinical examination.SUSS evaluation of all US scans
was performed. Areas evaluated included liver parenchyma (category A = normal,
B = increased echogenicity, C = coarse). Numerical scores (1 = normal, 2 = abnor-
mal)were assigned to hepatic Doppler traces, portal tracts and spleen size amongst
others. Score range A5 (normal)–C11 (abnormal).
Results: SUSS for CFnoLD and CFLD group at baseline and at 1 year showed
that 64% CFLD group had abnormal parenchyma & 42% abnormal scores. In the
CFnoLD group this was 19% and 9% respectively, whilst 27% and 74% had mild
changes.
Conclusion: Early results suggest that SUSS can be used for very early detection
of CFLD, even before LD becomes clinically & biochemically evident. It will be
helpful in deﬁning the natural history of CFLD.
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Introduction: Advances in medical management have improved life expectancy in
patients with cystic ﬁbrosis (CF). With prolonged survival CF associated liver disease
(CFLD) is now recognised as a major manifestation of CF with signiﬁcant morbidity.
Liver transplantation (LTx) is effective therapy in patients with CFLD and hepatic
dysfunction prior to deterioration of lung function.
Aim: To assess the long term outcome of LTx in children with CFLD in our unit.
Methods: Retrospective review of all children with CFLD transplanted between 1989–
2006. Data reviewed: demographic details, indications for LTx, diabetic status, survival,
renal function [calculated glomerular ﬁltration rate (cGFR) ml/min/1.73m2], lung
function and nutritional status.
Results: 19 children (12M, 7F) had LTx. Median age at transplant was 11.5 years
(2.1−16.5). Indications were progressive liver failure with deteriorating pulmonary
function (n = 18)and acute liver failure (n = 1).14/19 are alive. Median follow up is
7.5 years (0.6−15.5). 2/19 had retransplant (1 primary graft failure, 1 chronic rejection
after 9 years). 6 were diabetic pre LTx and 6 developed IDDM post LTx.
Summary: One and 5 year survival was 95% and 80% respectively, with an overall
long term survival rate of 72%.LTx for CFLD does not improve nutritional status, but
leads to improvement in lung function during ﬁrst two years.
Conclusion: LTx is effective therapy for CFLD.
Time Pre LTx, n = 19 Post 24m, n = 17 Post 60m, n = 11
Weight SDS Median (range) −0.6* (−4.2−1.2) −0.9 (−4.5−0.6) −1.7* (−5.2−0.08)
Height SDS Median (range) −1.3 (−3.0−1.1) −1.5 (−4.2−0.6) −1.4 (−4.3−0.8)
cGFR Median (range) 121.7 (77–165) 77.1 (53–149) 85.2 (38.0–105)
FEV1 SDS Median (range) −1.5 (−3.7−0.8) −1.1 (−3.8−0.5)
FVC SDS Median (range) −0.8 (−3.7−1.3) −0.4 (−2.8−0.8)
*p = 0.03, student T-test
